Elevation Oncology Inc [ELEV] stock is trading at $2.73, down -2.50%. An important factor to consider is whether the stock is rising or falling in short-term value. The ELEV shares have gain 16.17% over the last week, with a monthly amount drifted -27.78%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Elevation Oncology Inc [NASDAQ: ELEV] stock has seen the most recent analyst activity on May 31, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $10. Previously, Stephens started tracking the stock with Overweight rating on May 14, 2024, and set its price target to $8. On March 01, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $7 on the stock. SVB Securities upgraded its rating to a Outperform and increased its price target to $8 on May 30, 2023. H.C. Wainwright initiated its recommendation with a Buy and recommended $12 as its price target on December 23, 2021.
Elevation Oncology Inc [ELEV] stock has fluctuated between $0.36 and $5.83 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Elevation Oncology Inc [NASDAQ: ELEV] shares were valued at $2.73 at the most recent close of the market. An investor can expect a potential return of 229.67% based on the average ELEV price forecast.
Analyzing the ELEV fundamentals
Gross Profit Margin for this corporation currently stands at 0.33% with Operating Profit Margin at -664.98%, Pretax Profit Margin comes in at -677.86%, and Net Profit Margin reading is -678.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.59 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.59 points at the first support level, and at 2.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.82, and for the 2nd resistance point, it is at 2.95.
Ratios To Look Out For
For context, Elevation Oncology Inc’s Current Ratio is 46.22. On the other hand, the Quick Ratio is 46.22, and the Cash Ratio is 38.83.
